ClinicalTrials.gg
RecruitingNCT07169669BONEUpdated Nov 12, 2026

Multicentre Longitudinal Study of Bone Mineralisation Characteristics in Marfan Syndrome and Ehlers-Danlos Syndrome

An observational study in Marfan Syndrome, Ehlers-Danlos Syndrome (EDS) and Mineral Density, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by IRCCS Policlinico S. Donato · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 12, 2026Now RecruitingFirst site in Italy+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Marfan Syndrome with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Marfan Syndrome · Italy.

Started
2025
with 1 other
Observational
9 of 11
5 open now
Registered
10th of 11
by date
Lead sponsor
9 of 11
IRCCS Policlinico S. Donato

Among the 11 studies in Marfan Syndrome with a site in Italy, this one is one of 2 that started in 2025, is one of 9 observational ones, and was the 10th registered.

Marfan Syndrome

61 studies on the registry are indexed under Marfan Syndrome; 15 are open to participants now.

Browse Marfan Syndrome studies →

Open to participants now

5 of the 11 studies in Marfan Syndrome with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 12 Marfan Syndrome studies recruiting now, 7 (58%) set no upper age limit and 4 (33%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Marfan Syndrome with a site in Italy, or all of them as a file.
02

Study summary

General objective of this research is to evaluate the characteristics of bone mineralisation in patients with Marfan syndrome or Ehlers-Danlos syndrome on a large case series.

In particular aim is to obtain data regarding the characteristics of bone mineralisation, as well as their variation over time and the relationships existing with other clinical-anamnestic parameters, in patients with Marfan syndrome or Ehlers-Danlos syndrome by retrospectively analysing (data already collected for normal clinical practice and already available at the hospital) the case history of the Cardiovascular genetic center at IRCCS Policlinico San Donato and the related Computerized Bone Mineralometry (MOC) examinations performed at the Radiology Service of the same hospital between 1 September 2019 and 31 December 2022.

03

Conditions studied

  • Marfan Syndrome
  • Ehlers-Danlos Syndrome (EDS)
  • Mineral Density
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Marfan syndrome is a rare connective tissue disease with autosomal dominant transmission, characterised by altered production of the glycoprotein fibrillin-1 (FBN1), resulting from mutations in the gene encoding it.The complications most associated with the risk of mortality and morbidity are those affecting the cardiovascular system and those affecting the musculoskeletal system (spinal changes and chest deformities).

Ehlers-Danlos syndrome has an estimated prevalence of 1:5000 individuals and presents a pathological phenotype affecting the connective tissues that support the integumentary, skeletal, cardiovascular, and other organs and tissues. As in Marfan syndrome, marked alterations in the skeletal system (spine, thorax) and, in the vascular forms, a high risk of aneurysms and aortic and/or small and medium artery dissection, are found in those with Ehlers-Danlos syndrome.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with Marfan syndrome and Ehlers-Danlos syndrome according to the revised reference criteria belonging to the Cardiovascular genetic center at IRCCS Policlinico San Donato and the Reference Centre for Ehlers-Danlos Syndromes Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico;
  • Adult and paediatric subjects who have performed at least one Bone Mineral Densitometry within the observation period of the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of prostheses in the spinal column;
  • Presence of prostheses in the coxofemoral joint;
  • Oncological bone diseases reported in history.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Marfan group

    Adult and paediatric subjects with Marfan syndrome referred to the Centre for Cardiovascular Genetic of IRCCS Policlinico San Donato

  • Ehlers Danlos group

    Adult and paediatric subjects with Ehlers Danlos Syndrome referred to the Centre for CardioVascular Genetics of IRCCS Policlinico San Donato and the Reference Centre for Ehlers-Danlos Syndromes Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

06

What researchers measure

Primary outcomes

  1. Objective 1

    To retrospectively evaluate the percentage of subjects with fractures in subjects with Marfan syndrome and Ehlers Danlos syndrome who performed at least one Bone Mineral Densitometry in the period between 1 September 2019 and 31 January 2025.

    Time frame: Between 1 September 2019 and 31 January 2025.

Secondary outcomes

  1. Objective 2

    Identifying patients with osteoporosis with T-score values below -2.5 SD and z-score values ≤ -2 SD in the paediatric population.

    Time frame: Between 1 September 2019 and 31 January 2025.

  2. Objective 3

    Identify patients with osteopenia with T scores between -1 and -2.5 SD

    Time frame: Between 1 September 2019 and 31 January 2025.

  3. Objective 4

    Identify adult patients with TBS values * TBS values ≤ 1200 (degraded micro-architecture); * TBS values between 1349 - 1201 (partially degraded micro-architecture).

    Time frame: Between 1 September 2019 and 31 January 2025.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2026 → Mar 2027 and completion May 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 12, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Mar 31, 2027was Mar 2026
CompletionEst.
May 31, 2027was May 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added — first site in Italy
Show site
  • Cardiovascular Genetic Centre IRCCS Policlinico San Donato · San Donato Milanese, Italy
Nov 12, 2026
Primary completion
Mar 31, 2026→Mar 31, 2027
Nov 12, 2026
Study completion
May 31, 2026→May 31, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Italy
    Show site
    • Cardiovascular Genetic Centre IRCCS Policlinico San Donato · San Donato Milanese, Italy
    Primary completion Mar 31, 2026→Mar 31, 2027
    Study completion May 31, 2026→May 31, 2027
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07169669
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Oct 31, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Alessandro Pini Alessandro Giorgio Pini,MD, Medical degree
Contact
alessandro.pini@grupposandonato.it
(+39) 02 52774705

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion